S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:MITO

Stealth BioTherapeutics Stock Forecast, Price & News

$1.79
+0.07 (+4.07 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.64
Now: $1.79
$1.88
50-Day Range
$1.30
MA: $1.48
$1.72
52-Week Range
$0.90
Now: $1.79
$5.00
Volume626,973 shs
Average Volume448,412 shs
Market Capitalization$93.30 million
P/E Ratio44.76
Dividend YieldN/A
Beta2.25
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.

MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

727th out of 1,925 stocks

Pharmaceutical Preparations Industry

365th out of 773 stocks

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MITO
CUSIPN/A
CIKN/A
Phone617-600-6888
Employees73

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.09 million
Book Value$0.49 per share

Profitability

Net Income$-71,730,000.00

Miscellaneous

Market Cap$93.30 million
Next Earnings Date4/7/2021 (Estimated)
OptionableNot Optionable
$1.79
+0.07 (+4.07 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

How has Stealth BioTherapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MITO shares have increased by 12.7% and is now trading at $1.79.
View which stocks have been most impacted by COVID-19
.

Is Stealth BioTherapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Stealth BioTherapeutics?

Wall Street analysts have given Stealth BioTherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Stealth BioTherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Stealth BioTherapeutics' CEO?

1,448 employees have rated Stealth BioTherapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Stealth BioTherapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, April 7th 2021.
View our earnings forecast for Stealth BioTherapeutics
.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02).
View Stealth BioTherapeutics' earnings history
.

What price target have analysts set for MITO?

5 equities research analysts have issued twelve-month target prices for Stealth BioTherapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Stealth BioTherapeutics' share price to reach $8.00 in the next year. This suggests a possible upside of 346.9% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Stealth BioTherapeutics' key competitors?

What other stocks do shareholders of Stealth BioTherapeutics own?

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:
  • Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 56)
  • Mr. Robert J. Weiskopf, Chief Financial Officer (Age 69)
  • Mr. Henry Hess, Chief Legal Counsel
  • Mr. Mike Malynn, VP of HR
  • Dr. Ben R. Bronstein, Chief Medical Officer (Age 70)
  • Dr. Brian D. Blakey, Chief Bus. Officer (Age 58)
  • Dr. W. Douglas Weaver, Chief Medical Officer
  • Mr. James R. Carr, Chief Clinical Devel. Officer (Age 57)

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $1.79.

How big of a company is Stealth BioTherapeutics?

Stealth BioTherapeutics has a market capitalization of $93.30 million and generates $21.09 million in revenue each year. The company earns $-71,730,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Stealth BioTherapeutics employs 73 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.